肿瘤领域生物内CRO市场报告：依适应症、模式、应用和地区划分（2026-2034年）

2025年，全球肿瘤领域体内CRO市场规模达14亿美元。展望未来，IMARC集团预测，到2034年，该市场规模将达到25亿美元，2026年至2034年的复合年增长率为6.29%。癌症发生率上升、监管合规要求、技术持续进步以及对个人化医疗日益增长的需求，都是推动市场成长的因素。

肿瘤领域体内CRO市场的发展趋势：

癌症发生率上升

癌症发生率的上升是推动肿瘤体内CRO（合约研究组织）市场成长的关键因素。癌症仍是全球面临的一项重大公共卫生挑战，各类癌症的发生率持续上升。例如，国际癌症研究机构（IARC）2022年的调查报告显示，全球新增癌症病例约2000万例，死亡人数达900万，其中以肺癌和乳癌最为常见。同样，国际抗癌联盟（UICC）发表的报导预测，到2050年，癌症患者人数将达到3,500万人。癌症的复杂性要求采用个人化治疗方案，从而导致对CRO提供的临床试验和研究服务的需求增加。这些因素正积极影响肿瘤体内CRO市场的收入。

人们越来越关注个人化医疗

个人化医疗的日益普及是推动肿瘤领域体内CRO（合约研究组织）市场成长与发展的主要动力。例如，Statista估计，到2022年，个人化医疗、药物和诊断将占总收入的约40%。肿瘤是个人化医疗中最重要的治疗领域。为每位患者量身订做治疗方案可以提高疗效、减少副作用并改善整体治疗效果。这推动了对具备个人化医疗专业知识的CRO的需求，进而对肿瘤领域体内CRO产业的前景产生了正面影响。

技术进步

随着科技进步，肿瘤领域对体内CRO的需求日益增长。 PET-CT、MRI和分子影像等影像成像技术的进步使得在体内可视化和监测肿瘤成为可能。例如，2024年6月，西门子医疗在美国核子医学与分子影像学会年会上发布了其最新的PET/CT扫描器Biograph Trinion。此扫描仪的检测器采用镏氧硅酸盐（LSO）晶体元件，实现了高空间解析度和239皮秒的超快飞行时间。这使得它能够侦测到微小病灶，并展现出高达128 cps/kBq的高灵敏度。因此，它能够实现高速扫描并降低患者的辐射计量。这有助于更准确地追踪疾病进展和治疗反应。这些因素进一步推动了肿瘤体内CRO市场的收入成长。

目录

第一章：序言

第二章：调查方法

• 调查目的
• 相关利益者
• 数据来源
  • 主要讯息
  • 二手资讯
• 市场估值
  • 自下而上的方法
  • 自上而下的方法
• 预测方法

第三章执行摘要

第四章：引言

第五章：肿瘤领域全球体内CRO市场

• 市场概览
• 市场表现
• 新冠疫情的影响
• 市场预测

第六章 市场区隔：依适应症划分

• 血癌
• 固体癌
• 其他的

第七章 市场区隔：依模型

• 有关的
• 异种移植
• 患者来源的异质骨移植（PDX）
• 其他的

第八章 市场区隔：依应用领域划分

• 医院
• 復健中心

第九章 市场区隔：依地区划分

• 北美洲
  • 我们
  • 加拿大
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 韩国
  • 澳洲
  • 印尼
  • 其他的
• 欧洲
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙
  • 俄罗斯
  • 其他的
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 其他的
• 中东和非洲

第十章 SWOT 分析

第十一章：价值链分析

第十二章：波特五力分析

第十三章：价格分析

第十四章 竞争格局

• 市场结构
• 主要企业
• 主要企业简介
  • Champions Oncology Inc.
  • Charles River Laboratories International Inc.
  • Crown Bioscience Inc.
  • Eurofins Scientific
  • Evotec SE
  • ICON Plc
  • Labcorp Drug Development（Laboratory Corporation of America Holdings）
  • Living Tumor Laboratory
  • Taconic Biosciences Inc.
  • The Jackson Laboratory
  • WuXi AppTec
  • Xentech

The global oncology based in-vivo CRO market size reached USD 1.4 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 2.5 Billion by 2034, exhibiting a growth rate (CAGR) of 6.29% during 2026-2034. The rising prevalence of cancer, regulatory compliances, ongoing technological advancements, and the surging demand for personalized medicines are driving the market growth.

ONCOLOGY BASED IN-VIVO CRO MARKET ANALYSIS:

• Major Market Drivers: The growing prevalence of cancer around the world represents one of the key factors driving the market. Moreover, governments of several countries across the globe are extensively investing in research and development (R&D) activities, which is driving industry's growth.
• Key Market Trends: The wide availability of personalized treatment techniques, along with the expanding healthcare industry, is catalyzing the demand for oncology based in-vivo CRO worldwide. Additionally, there is an increase in the adoption of telehealth and virtual clinical trials in the healthcare industry to ensure the safety of cancer patients. This is projected to bolster the growth of the market.
• Competitive Landscape: Some of the prominent oncology based in-vivo CRO market companies in the market include Champions Oncology Inc., Charles River Laboratories International Inc., Crown Bioscience Inc., Eurofins Scientific, Evotec SE, ICON Plc, Labcorp Drug Development (Laboratory Corporation of America Holdings), Living Tumor Laboratory, Taconic Biosciences Inc., The Jackson Laboratory, WuXi AppTec, and Xentech, among many others.
• Geographical Trends: According to the oncology based in-vivo CRO market dynamics, North America exhibits a clear dominance in the market. The prevalence of various types of cancer continues to increase in the region, driving oncology based in-vivo CRO market demand.
• Challenges and Opportunities: Regulatory and compliance burden, and the increasing demand for customized clinical trial protocols are hampering the market growth. However, AI-driven algorithms for data analytics, predictive modeling, and patient stratification enhance efficiency and decision-making in oncology research.

ONCOLOGY BASED IN-VIVO CRO MARKET TRENDS:

Rising Prevalence of Cancer

The rising prevalence of cancer is a significant driver behind the growth of the oncology-based in-vivo Contract Research Organization (CRO) market. Cancer continues to be a major public health challenge worldwide, with increasing incidence rates across various types of cancers. For instance, the IARC's 2022 study showed around 20 million new cancer cases and nearly nine million deaths worldwide, with lung and breast cancer being the most common. Similarly, according to an article published by the Union for International Cancer Control, cancer cases are projected to rise to 35 million by 2050. The complexity of cancer requires tailored treatment approaches, leading to a higher demand for clinical trials and research services provided by CROs. These factors are positively influencing the oncology based in-vivo CRO market revenue.

Increasing Emphasis on Personalized Medicine

The increasing emphasis on personalized medicine is a major driver behind the growth and evolution of the oncology-based in-vivo Contract Research Organization (CRO) market. For instance, according to Statista, personalized medical care, medicines, and diagnostics were estimated to account for around 40% of total revenue in 2022. Oncology is the most significant therapeutic area for personalized medicine. Tailoring treatments to individual patients improves efficacy, reduces adverse effects, and enhances overall treatment outcomes, driving the demand for CROs with expertise in personalized medicine, thereby positively influencing the oncology based in-vivo CRO industry forecast.

Technological Advancements

Increasing technological advancements are escalating the demand for oncology-based in-vivo Contract Research Organizations. Improved imaging modalities, such as PET-CT, MRI, and molecular imaging techniques have enabled better visualization and monitoring of tumors in vivo. For instance, in June 2024, Siemens Healthineers launched the Biograph Trinion, their latest PET/CT scanner, at the annual meeting of the Society of Nuclear Medicine and Molecular Imaging. The scanner's detector is based on lutetium oxyorthosilicate (LSO) crystal elements and delivers high spatial resolution and an ultrafast time-of-flight performance of 239 picoseconds for small lesion detectability and effective sensitivity up to 128 cps/kBq, allowing for fast scans and low patient radiation doses. This enhances the ability to track disease progression and response to treatments more accurately. These factors are further bolstering the oncology-based in-vivo CRO market revenue.

GLOBAL ONCOLOGY BASED IN-VIVO CRO INDUSTRY SEGMENTATION:

Breakup by Indication:

• Blood Cancer
• Solid Tumors
• Others

Solid tumors currently represent the largest market share

According to the oncology-based in-vivo CRO market outlook, solid tumors are the most common type of cancer, encompassing a wide range of malignancies such as breast, lung, colorectal, and prostate cancers. Their prevalence ensures a large patient population for clinical trials, making them attractive for CROs and pharmaceutical companies. Moreover, there has been a significant increase in the number of cancer patients. For instance, the American Cancer Society, the major source of cancer statistics and data, estimated nearly 1,685,210 new cancer cases and 595,690 deaths in the United States in 2021.

Breakup by Model:

• Syngeneic
• Xenograft
• Patient Derived Xenograft (PDX)
• Others

Currently, Patient Derived Xenograft (PDX) model accounts for the majority of the total market share

According to the oncology-based in-vivo CRO market overview, PDX models involve implanting patient-derived tumor tissue into immunodeficient mice, thereby preserving the molecular and histological characteristics of the original tumor. This model closely mimics human tumor biology and heterogeneity, making it invaluable for studying cancer progression, metastasis, and treatment response. Moreover, these models are highly predictive of patient response to therapies, including chemotherapy, targeted therapy, and immunotherapy. Pharmaceutical companies and biotech firms rely on PDX studies to assess drug efficacy, optimize treatment regimens, and identify potential biomarkers for patient stratification.

Breakup by Application:

• Hospitals
• Rehabilitation Centers

The oncology-based in-vivo CRO market report has provided a detailed breakup and analysis of the market based on the application. This includes hospitals and rehabilitation centers.

Hospitals frequently collaborate with CROs to conduct clinical trials for evaluating new oncology treatments. CROs provide expertise in study design, protocol development, patient recruitment, and regulatory compliance, enabling hospitals to participate in cutting-edge research without diverting resources from patient care. While rehabilitation centers may participate in clinical trials focused on cancer survivors who require rehabilitation services to improve their quality of life post-treatment. CROs can support such trials by providing expertise in study design, outcome measures, and data management specific to this patient population.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America currently dominates the global market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

According to the oncology based in-vivo CRO market statistics, the rising incidence of cancer cases in North America continues to drive demand for innovative therapies and treatment options. For instance, the Globocan 2021 report estimated that nearly 2,281,000 new cancer cases were diagnosed in the United States in 2021, with almost 612,000 fatalities. Oncology-focused CROs play a critical role in advancing research and development efforts to address unmet medical needs across various cancer types. Moreover, continuous advancements in technology, including molecular profiling, genomic sequencing, imaging modalities (such as PET-CT and MRI), and high-throughput screening platforms, enhance the capabilities of CROs to conduct sophisticated in-vivo studies. These technologies enable precise characterization of tumors, identification of biomarkers, and evaluation of therapeutic efficacy, contributing to the growth of oncology based CRO services.

COMPETITIVE LANDSCAPE:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

• Champions Oncology Inc.
• Charles River Laboratories International Inc.
• Crown Bioscience Inc.
• Eurofins Scientific
• Evotec SE
• ICON Plc
• Labcorp Drug Development (Laboratory Corporation of America Holdings)
• Living Tumor Laboratory
• Taconic Biosciences Inc.
• The Jackson Laboratory
• WuXi AppTec
• Xentech

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What was the size of the global oncology based in-vivo CRO market in 2025?

2. What is the expected growth rate of the global oncology based in-vivo CRO market during 2026-2034?

3. What are the key factors driving the global oncology based in-vivo CRO market?

4. What has been the impact of COVID-19 on the global oncology based in-vivo CRO market?

5. What is the breakup of the global oncology based in-vivo CRO market based on the indication?

6. What is the breakup of the global oncology based in-vivo CRO market based on the model?

7. What are the key regions in the global oncology based in-vivo CRO market?

8. Who are the key players/companies in the global oncology based in-vivo CRO market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Oncology Based In-Vivo CRO Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Indication

• 6.1 Blood Cancer
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Solid Tumors
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Others
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Model

• 7.1 Syngeneic
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Xenograft
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Patient Derived Xenograft (PDX)
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Application

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Rehabilitation Centers
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Champions Oncology Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
  • 14.3.2 Charles River Laboratories International Inc.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Crown Bioscience Inc.
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 Eurofins Scientific
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Evotec SE
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 ICON Plc
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 Labcorp Drug Development (Laboratory Corporation of America Holdings)
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 SWOT Analysis
  • 14.3.8 Living Tumor Laboratory
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
  • 14.3.9 Taconic Biosciences Inc.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
  • 14.3.10 The Jackson Laboratory
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
  • 14.3.11 WuXi AppTec
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
  • 14.3.12 Xentech
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio

List of Figures

• Figure 1: Global: Oncology Based In-Vivo CRO Market: Major Drivers and Challenges
• Figure 2: Global: Oncology Based In-Vivo CRO Market: Sales Value (in Billion USD), 2020-2025
• Figure 3: Global: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Billion USD), 2026-2034
• Figure 4: Global: Oncology Based In-Vivo CRO Market: Breakup by Indication (in %), 2025
• Figure 5: Global: Oncology Based In-Vivo CRO Market: Breakup by Model (in %), 2025
• Figure 6: Global: Oncology Based In-Vivo CRO Market: Breakup by Application (in %), 2025
• Figure 7: Global: Oncology Based In-Vivo CRO Market: Breakup by Region (in %), 2025
• Figure 8: Global: Oncology Based In-Vivo CRO (Blood Cancer) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 9: Global: Oncology Based In-Vivo CRO (Blood Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 10: Global: Oncology Based In-Vivo CRO (Solid Tumors) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 11: Global: Oncology Based In-Vivo CRO (Solid Tumors) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 12: Global: Oncology Based In-Vivo CRO (Other Indications) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 13: Global: Oncology Based In-Vivo CRO (Other Indications) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 14: Global: Oncology Based In-Vivo CRO (Syngeneic) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 15: Global: Oncology Based In-Vivo CRO (Syngeneic) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 16: Global: Oncology Based In-Vivo CRO (Xenograft) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 17: Global: Oncology Based In-Vivo CRO (Xenograft) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 18: Global: Oncology Based In-Vivo CRO (Patient Derived Xenograft (PDX)) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 19: Global: Oncology Based In-Vivo CRO (Patient Derived Xenograft (PDX)) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 20: Global: Oncology Based In-Vivo CRO (Other Models) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 21: Global: Oncology Based In-Vivo CRO (Other Models) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 22: Global: Oncology Based In-Vivo CRO (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 23: Global: Oncology Based In-Vivo CRO (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 24: Global: Oncology Based In-Vivo CRO (Rehabilitation Centers) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 25: Global: Oncology Based In-Vivo CRO (Rehabilitation Centers) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 26: North America: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
• Figure 27: North America: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 28: United States: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
• Figure 29: United States: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 30: Canada: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
• Figure 31: Canada: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 32: Asia-Pacific: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
• Figure 33: Asia-Pacific: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 34: China: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
• Figure 35: China: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 36: Japan: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
• Figure 37: Japan: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 38: India: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
• Figure 39: India: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 40: South Korea: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
• Figure 41: South Korea: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 42: Australia: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
• Figure 43: Australia: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 44: Indonesia: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
• Figure 45: Indonesia: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 46: Others: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
• Figure 47: Others: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 48: Europe: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
• Figure 49: Europe: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 50: Germany: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
• Figure 51: Germany: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 52: France: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
• Figure 53: France: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 54: United Kingdom: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
• Figure 55: United Kingdom: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 56: Italy: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
• Figure 57: Italy: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 58: Spain: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
• Figure 59: Spain: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 60: Russia: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
• Figure 61: Russia: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 62: Others: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
• Figure 63: Others: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 64: Latin America: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
• Figure 65: Latin America: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 66: Brazil: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
• Figure 67: Brazil: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 68: Mexico: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
• Figure 69: Mexico: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 70: Others: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
• Figure 71: Others: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 72: Middle East and Africa: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
• Figure 73: Middle East and Africa: Oncology Based In-Vivo CRO Market: Breakup by Country (in %), 2025
• Figure 74: Middle East and Africa: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 75: Global: Oncology Based In-Vivo CRO Industry: SWOT Analysis
• Figure 76: Global: Oncology Based In-Vivo CRO Industry: Value Chain Analysis
• Figure 77: Global: Oncology Based In-Vivo CRO Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Oncology Based In-Vivo CRO Market: Key Industry Highlights, 2025 and 2034
• Table 2: Global: Oncology Based In-Vivo CRO Market Forecast: Breakup by Indication (in Million USD), 2026-2034
• Table 3: Global: Oncology Based In-Vivo CRO Market Forecast: Breakup by Model (in Million USD), 2026-2034
• Table 4: Global: Oncology Based In-Vivo CRO Market Forecast: Breakup by Application (in Million USD), 2026-2034
• Table 5: Global: Oncology Based In-Vivo CRO Market Forecast: Breakup by Region (in Million USD), 2026-2034
• Table 6: Global: Oncology Based In-Vivo CRO Market: Competitive Structure
• Table 7: Global: Oncology Based In-Vivo CRO Market: Key Players